Precision Benefit Design: How should the arrival of precision medicine affect health plan benefit design?
Advances in precision medicine offer the promise of tremendous gains in patient health over the coming decades. Headlines in the popular press as well as discussions at academic conferences tout the potential benefits of precision [...]
Is One Answer Good Enough for All? Defining Value in Healthcare
While it makes sense for value assessment to be woven into healthcare decision making, relying on a single method to measure value and using this metric to restrict treatment access is shortsighted. IVI's Jennifer Bright [...]
Why Quality Measures Must Reflect Patient Values, Care Experience
There isn't an easy answer to assessing value in healthcare, but IVI is working to tackle the problems through considerable research and experimentation by developing an open-source value platform that considers no only clinical factors, [...]
Is Using Centralized Value Assessment to Make Centralized Pricing Decisions the Most Effective Path Forward?
The Pink Sheet article described comment letters to HHS’ drug pricing blueprint recommending that cost-effectiveness analyses by ICER could help promote value-based pricing in government-sponsored insurance. While IVI concurs value assessment is noble, worthwhile and [...]
IVI Provides Insight into CVS Health’s Decision to Include Cost-per-QALY Analyses from ICER into Formulary Decision-Making
CVS Health's pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI's Director [...]
How to Improve Value Assessment
In an op-ed published in Healthcare Business News, IVI's Executive Director, Jennifer Bright, describes four essential steps necessary to better measure value in healthcare: Better value measurement must incorporate the patient perspective into all assessment [...]
PRESS RELEASE: IVI Responds to HHS’ Blueprint Saying Lowering Healthcare Costs Requires Improving Value Assessment
IVI Says Moving Beyond Cost Effectiveness by Evaluating Treatments Based on Unique Patient Characteristics and Preferences is Imperative Los Angeles, CA – July 16, 2018 -- If we are going to truly harness data [...]
Current Problems with Value Assessments and Ideas for Improvement
In an op-ed published by Fierce Healthcare, Director of Scientific Communications, Mark Linthicum discusses current shortfalls of value assessment and what is needed to move to value assessment 2.0. Read the full article here.
PRESS RELEASE: Why IVI’s Next Open-Source Modeling Platform Will Focus on Value in Lung Cancer
Los Angeles, CA -- June 20, 2018 -- Oncology is both an area of immense clinical need and a primary driver of healthcare spending. As a result, cancer care is a focus of extensive [...]
An Open-Source Approach Will Drive Healthcare Value Assessment 2.0
Measuring value in healthcare, which frequently takes the perspective of a single payer managing population health and costs, needs to evolve to include diverse perspectives and provide relevant and actionable information on value to [...]
PRESS RELEASE: IVI’s Open-Source Value Project Produces Actionable Data on Value of Rheumatology Treatment Sequencing Designs
Washington, D.C. -- June 14, 2018 -- Measuring value in healthcare, which traditionally takes the perspective of a single payer managing population health and costs, needs to evolve to include diverse perspectives and provide [...]
IVI Leadership Invited to Speak at the 2018 BIO International Convention
The 2018 BIO International Convention will be held in Boston, MA from June 4th through June 7th. IVI’s Jennifer Bright (Acting Executive Director) and Mark Linthicum (Director of Scientific Communications) are among the speakers invited [...]